Harmonization of Serum Thyroid-Stimulating Hormone Measurements Paves the Way for the Adoption of a More Uniform Reference Interval L.M. Thienpont, K.

Slides:



Advertisements
Similar presentations
Between-Method Differences in Prostate Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms C. Stephan, K. Siemβen, H. Cammann,
Advertisements

Harmonization of Measurement Results of the Alcohol Biomarker Carbohydrate- Deficient Transferrin by Use of the Toolbox of Technical Procedures of the.
Supplemental Data Fig. 1. Results from commutability study for hGH. Plotted are the measurement results for clinical samples, hGH preparations, and control.
The Importance of Commutability of Reference Materials Used as Calibrators: The Example of Ceruloplasmin I. Zegers, R. Beetham, T. Keller, J. Sheldon,
All you wanted to know about laboratory tests, but were afraid to ask By Dietmar Stöckl STT Consulting The informed patient meeting the laboratory.
Utilization of Assay Performance Characteristics to Estimate Hemoglobin A 1c Result Reliability A. Woodworth, N. Korpi-Steiner, J.J. Miller, L.V. Rao,
Measurements for 8 Common Analytes in Native Sera Identify Inadequate Standardization among 6 Routine Laboratory Assays H.C.M. Stepman, U. Tiikkainen,
Introduction to ISO New and modified requirements.
Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,
Accuracy of 6 Routine 25-Hydroxyvitamin D assays; Influence of Vitamin D Binding Protein Concentration A.C. Heijboer, M.A. Blankenstein, I.P. Kema, and.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
Statistics & graphics for the laboratory 25 Biological variation Introduction Estimation (ANOVA application) Index-of-individuality Comparison of a result.
Use of Reference Materials in Medical Testing SLAB 10th Anniversary Celebrations Accreditation Conference 10 th November 2015 Dr Deepani Siriwardhana Senior.
Quality control & Statistics. Definition: it is the science of gathering, analyzing, interpreting and representing data. Example: introduction a new test.
Comparability of methods and analysers Nora Nikolac
© The Strategic Projects Team Hosted by the Greater East Midlands Commissioning Support Unit National Pathology Programme Standardisation and Harmonisation.
Diana Careaga 1, Robert Magari 1, Karen Lo 1, Michael Keeney 2, Ben Hedley 2, Dominika Benjamins 2, Dr. You-Wen Qian 3, Larry Hinson 3, Cristina Ceja 3,
Introduction The composition of plasma and Cerebrospinal fluid (CSF) are similar with the only major difference between the two being the greatly reduced.
Method comparisons - what do we learn from the Nordic Reference Interval Project 2000 (NORIP) Pål Rustad Fürst Medical Laboratory Labquality Days 12/
Cepheid Symposium IAS 2017 Gwynn Stevens, PhD Director of Virology
Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.
Josiane Arnaud1, Jean-Philippe Weber2,
Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides A. K. Saenger, O. Rodriguez-Fraga,
Update on the Alzheimer’s Association Quality Control (QC) program
Harmonization of Thyroid Stimulating Hormone (TSH); an Alternative Approach   Author: Izza Abdulhafedh Laboratory Scientist, The Nairobi Hospital, Kenya.
Unit #6 - Basic Quality Control for the Clinical Laboratory
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
PSEUDO-HYPERTHYROXINAEMIA
Fig. 2. Distribution of vitamin D levels of all samples by Siemens, Abbott, and DiaSorin. The mean (SD) of Siemens, Abbott, and DiaSorin assays was
Evaluation of the Tosoh Bioscience 25OH vitamin D assay
EVALUATION OF HEMOCHROMA POC Hb READER
Establishment of reference intervals for sex hormone binding globulin, LC-MS/MS derived free androgen index and calculated free testosterone SN Duignan,
2017 Update on the Alzheimer’s Association
Joint Committee for Traceability in Laboratory Medicine
Effect of GnRH-agonist downregulation on serum AMH levels: a prospective cohort study with repeated measurements P. Drakopoulos1, A. van de Vijver1, J.
Laboratory Quality Control
MarketsandMarkets Presents Clinical Chemistry Analyzers Market worth $11, Million by
MarketsandMarkets Presents Technology Advancement in Clinical Chemistry Analyzers Market
MarketsandMarkets Presents Growth of Clinical Chemistry Analyzers Market worth $11, Million by
MarketsandMarkets Presents Forecast Market Size and Share of Global clinical chemistry analyzer Market & its Trends
MarketsandMarkets Presents How the Market Factors Impact on clinical chemistry analyzer Market Industry in Future
MarketsandMarkets Presents Global Clinical Chemistry Market for Academic Research Institutes
MarketsandMarkets Presents Global Clinical Chemistry Market is expected to grow at a CAGR of 5.52% during forecast
Update on ASTM and Standard Methods method development activities
به نام خدا تضمين کيفيت در آزمايشگاه
Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle  Michael W.
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications  Vera Grossmann, Andreas Roller, Hans-Ulrich Klein, Sandra Weissmann,
Integration of CRM by Companies
Nat. Rev. Nephrol. doi: /nrneph
W. Greg Miller, Graham R.D. Jones  Advances in Chronic Kidney Disease 
Inter-Laboratory Comparison Exercise CPC CALIBRATION
Volume 87, Issue 1, Pages (July 2015)
Volume 94, Issue 4, Pages e7 (May 2017)
Differential Impact of Behavioral Relevance on Quantity Coding in Primate Frontal and Parietal Neurons  Pooja Viswanathan, Andreas Nieder  Current Biology 
Anil Vachani, MD, Harvey I. Pass, MD, William N. Rom, MD, David E
Responses of Collicular Fixation Neurons to Gaze Shift Perturbations in Head- Unrestrained Monkey Reveal Gaze Feedback Control  Woo Young Choi, Daniel.
Jianing Yu, David Ferster  Neuron 
Nicolas Catz, Peter W. Dicke, Peter Thier  Current Biology 
FIGURE 1A Abbott Architect i2000 (I) Abbott Architect i2000 (I) Ratio
Quality Control Lecture 3
Kevin Wood Bieri, Katelyn N. Bobbitt, Laura Lee Colgin  Neuron 
Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott 
Fan Zheng, Jian Zhang, Gevorg Grigoryan  Structure 
A proposal for Derivation of Analytical Quality Goal for Precision
STANDARDISATION, HARMONISATION AND TRACEABILITY
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA  Justin T. Brown, Ion J. Beldorth,
Thyroid hormones.
Published by :Accurize Market Research Pvt. Ltd. Copyright © 2019 Accurize Market Research Global Microfluidic Devices.
CPSA 4 Corners Initiative 2018
STATISTICS INFORMED DECISIONS USING DATA
Presentation transcript:

Harmonization of Serum Thyroid-Stimulating Hormone Measurements Paves the Way for the Adoption of a More Uniform Reference Interval L.M. Thienpont, K. Van Uytfanghe, L.A.C. De Grande, D. Reynders, B. Das, J. D. Faix, F. MacKenzie, B. Decallonne, A. Hishinuma, B. Lapauw, P. Taelman, P. Van Crombrugge, A. Van den Bruel, B. Velkeniers, P. Williams July 2017 www.clinchem.org/content/63/7/1248.full © Copyright 2017 by the American Association for Clinical Chemistry

Introduction Measurement of serum thyroid hormone concentrations is an indispensable tool to confirm and follow-up thyroid disease Reference intervals (RI) reported along with the laboratory data are an integral part of the interpretation process The IFCC Committee for Standardization of Thyroid Function Tests (C-STFT) developed a global harmonization approach for thyroid-stimulating hormone (TSH) measurements Here we describe the Phase IV method comparison and RI studies conducted with the objective to recalibrate the participating assays and establish the proof-of-concept See Editorial by Miller WG. Harmonization: Its Time Has Come. Clin Chem 2017.

Questions What is unique in the design of the harmonization and proof-of-concept/RI studies?

Materials and methods – Study design Harmonization based on a multiassay method comparison study Two panels of clinically relevant samples used in the Phase IV method comparison study: the harmonization (n = 101) and first follow-up panel (n = 95) Targets set with a robust factor analysis method and use of the results of 4 IVD manufacturers who measured both panels in the same run (n = 196) (target referred to as “APTM-4”) Harmonization (= recalibration to the targets) directly done by the participating IVD manufacturers (n = 14): see Table 1 Proof-of-concept/RI study done with a panel of 120 samples donated by “apparently healthy” American volunteers

IVD manufacturer - Platform/Assay Table 1. Phase IV study participants (ordered by code given), inclusive the platforms/TSH assays. IVD manufacturer - Platform/Assay Code Siemens Healthineers (Tarrytown, NY) - Advia Centaur XP Ac Abbott Diagnostics (Abbott Park, IL) - Architect i2000 Bc aShenzhen Mindray Bio-Medical Electronics Co., Ltd. (Shenzhen, China) - CL-2000i C Ortho-Clinical Diagnostics (Buckinghamshire, UK) - Vitros Eci D bioMérieux SA (Marcy-l’Etoile, France) – Vidas E Beckman Coulter Inc. (Brea, CA) - Access 2 F DiaSorin S.p.A (Saluggia, Italy) - Liaison® Analyser G aSichuan Maccura Biotechnology Co., Ltd (Chengdu, China) - IS1200 H Roche Diagnostics GmbH (Mannheim, Germany) - Elecsys (Cobas e 601) Ic Tosoh Corporation (Tokyo, Japan) - AIA-2000 Jc aSnibe Co., Ltd. (Shenzhen, China) - Maglumi 2000 K aFujirebio Inc. (Tokyo, Japan) - Lumipulse G1200 L bLSI Medience Corporation (Tokyo, Japan) - STACIA N bSysmex Corporation (Kobe, Japan) - HISCL-5000 O a,b Manufacturers who only joined in 2015a and/or 2016b for participation in the Phase IV method comparison study c Data from these manufacturers were used to calculate the APTM-4

Materials and methods – Measurement protocol Phase IV method comparison study Samples measured in singlicate, on each of 2 days Individual results reported Master calibrators included Recalibration of the assays Master calibrators of each assay value reassigned to the APTM-4 by use of the company’s in-house mathematical procedure Results for the patient samples recalculated as if the revised master calibrators were used for calibration RI study Samples measured in singlicate, within run Results mathematically transformed using the value reassigned master calibrators Pre- and postrecalibration results reported

Materials and methods – Data treatment Demonstrate/validate the suitability of the recalibrated results to meet analytical specifications based on biological variation (bias: 7.8%; total error: 23.8%) Estimate the pre- and postrecalibration RI characteristics (2.5th, 50th and 97.5th percentiles, each with their 90% CIs) For each assay and the overall results (after applying the robust factor analysis model on the results of the 14 participating assays) RI characteristics estimated with the nonparametric bootstrap procedure (n = 500) Investigate the effect of recalibration on the uniformity of the RI characteristics (= proof-of-concept)

Questions What were the main findings of the study?

Results – Method comparison/RI studies The concentration ranges (based on the APTM-4) covered by the panels are: Harmonization panel: 0.002 – 193 mIU/L First follow-up panel: 0.002 – 169 mIU/L The overall relative uncertainty of the targets ranges from 0.7% to 1.0% The first follow-up panel is linked/traceable to the harmonization panel (because measured in parallel) and has an identical uncertainty Can be used to harmonize new assays in the future Assures the sustainability of the traceability anchor established with the harmonization panel Recalibration of the assays by the IVD manufacturers is successful (see Figures 1, 2 and 3)

Figure 1. Combined difference (%) plots to the APTM-4 before (A) and after recalibration (B). For each assay and sample, the difference of the mean from duplicate measurements is plotted Filled and colored circles: differences of the assays that were most discrepant before recalibration Open black circles: all other assays Red broken lines: 7.8% bias limits Blue broken lines: 15th and 85th centiles of the differences Recalibration eliminates the calibration differences between the assays

Recalibration reduces the range of the median deviations (%) Figure 2. Median deviations (%) of the assays to the APTM-4 before and after recalibration in 3 concentration intervals: low: < 0.5 mIU/L, mid: ≥ 0.5 < 5.0 mIU/L, high: ≥ 5.0 mIU/L. For each concentration interval, 2 pairs of data are shown Black and red dots: the combined assay-specific median deviations before and after recalibration, respectively Black and red lines: 15th, 50th, and 85th centiles Recalibration reduces the range of the median deviations (%)

After recalibration the uniformity of the RIs is improved Figure 3. Comparison of the pre- and postrecalibration reference intervals of the assays to the overall RI. Pre-recalibration RI: orange Post-recalibration RI: blue Thick horizontal bars: the 2.5th, 50th and 97.5th percentiles Thin vertical lines: the 90% CIs of the respective percentiles Grey and blue broken horizontal lines: the post-recalibration 2.5th, 50th and 97.5th reference percentiles and their respective 90% CIs After recalibration the uniformity of the RIs is improved

Conclusions The C-STFT global approach for TSH harmonization shows improved comparability between assays and gives evidence that more uniform RIs may be achieved in the near future The presented postrecalibration RI is not the final one but a good starting point for IVD manufacturers to verify their RIs in accordance with accepted consensus standards The follow-up panel warrants that in the future new assays can be harmonized to the traceability anchor established in this Phase IV study The traceability anchor needs to be sustained by developing new follow-up panels and target setting always in overlap with the previous one before it is depleted

Final Comment in Editorial “This report of a successful harmonization protocol is an important advance in laboratory medicine because it demonstrates an approach to achieve fit-for-purpose agreement among patient results measured by different measurement procedures when a certified reference material or reference measurement procedure is not available for calibration traceability.” Miller WG. Harmonization: Its Time Has Come. Clin Chem 2017.